Buckingham Palace Drops the Bombshell News Ahead of Prince Harry’s UK Return
Buckingham Palace has delivered somber news just before the anticipated return of Prince Harry to Britain for the Invictus Games event.
The royal family disclosed the ‘sad news’ surrounding the passing of Kris Hallenga, founder of the CoppaFeel! breast cancer charity, who succumbed to the disease at the age of 38 after battling it for 15 years.
CoppaFeel! shared a heartfelt announcement accompanied by a photo of Kris, stating, “We share the sad news that our founder, boob chief, colleague, friend, and queen of glittering turds, Kris, has died.”
The post further celebrated Kris’s vibrant approach to life, noting her creativity, fearlessness, and determination to live fully despite her diagnosis.
Kris’s journey began in 2009 when she was diagnosed with secondary breast cancer at the young age of 23, having been initially turned away by her GP for over a year.
Tragically, by the time of her diagnosis, the cancer had progressed to a terminal stage.
However, Kris’s resolve to spare others from a similar fate led her to establish CoppaFeel!, dedicated to promoting early and accurate diagnosis of breast cancer.
Expressing condolences on behalf of King Charles and Queen Camilla, the royal family retweeted CoppaFeel!’s tribute to Kris.
Read More: Cillian Murphy’s Spiteful and Bold Gesture Against Prince Harry Raises Eyebrows
The timing of the announcement, just ahead of Prince Harry’s imminent arrival in the UK to commemorate the 10th anniversary of the Invictus Games, adds a poignant layer to the collective mourning.
As Prince Harry prepares to return to his homeland for a significant milestone in his philanthropic efforts, the news of Kris Hallenga’s passing serves as a poignant reminder of the ongoing battles faced by individuals and families affected by cancer.
In honoring Kris’s legacy, there is a renewed call to continue the fight for early detection and improved outcomes in the relentless pursuit of a world free from the scourge of breast cancer.